908 Devices/$MASS
1D1W1MYTD1Y5YMAX
Capital at risk
About 908 Devices
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.
- Ticker
- $MASS
- Sector
- Digital Hardware
- Primary listing
- NASDAQ
- Employees
- 172
- Headquarters
- Burlington, United States
- Website
- 908devices.com
908 Devices Metrics
BasicAdvanced
$386M
-
-$0.94
0.63
-
Price and volume
Market cap
$386M
Beta
0.63
52-week high
$11.25
52-week low
$5.03
Average daily volume
469K
Financial strength
Current ratio
2.671
Quick ratio
2.291
Long term debt to equity
2.826
Total debt to equity
3.39
Profitability
EBITDA (TTM)
-16.832
Gross margin (TTM)
52.65%
Net profit margin (TTM)
-56.96%
Operating margin (TTM)
-34.84%
Effective tax rate (TTM)
0.55%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-6.92%
Return on equity (TTM)
-24.95%
Valuation
Price to revenue (TTM)
5.643
Price to book
2.81
Price to tangible book (TTM)
5.04
Price to free cash flow (TTM)
558.276
Free cash flow yield (TTM)
0.18%
Free cash flow per share (TTM)
0.017
Growth
Revenue change (TTM)
13.35%
Earnings per share change (TTM)
80.13%
3-year revenue growth (CAGR)
7.47%
3-year earnings per share growth (CAGR)
-7.43%
What the Analysts think about 908 Devices
Analyst ratings (Buy, Hold, Sell) for 908 Devices stock.
Analyst projections of the future price of 908 Devices stock.
Bulls say / Bears say
Revenue rose 23% year-over-year in Q2 2026 to $16.1 million, driven by stronger VipIR product sales and the contribution from the NIRLab acquisition, demonstrating successful product diversification and robust demand. (SEC Q2 10-Q)
Adjusted EBITDA loss narrowed to $1.9 million in Q2 2026 from $3.9 million in the prior-year period, while adjusted gross margin expanded to 57%, indicating meaningful progress toward profitability. (SEC Q2 10-Q)
Management raised full-year 2026 revenue guidance to $68.0 million–$70.0 million, up from $67.0 million–$70.0 million, reflecting confidence in continued mid-20% growth momentum. (SEC Q2 10-Q)
Despite improvements, the company still reported an adjusted EBITDA loss of $1.9 million in Q2 2026, underscoring that it has yet to achieve sustained profitability. (SEC Q2 10-Q)
Recurring revenue represented only 31% of total revenue in Q2 2026, indicating a heavy reliance on one-time device sales and potential volatility in revenue streams. (SEC Q2 10-Q)
Cash, cash equivalents, and marketable securities declined from $112.97 million at December 31, 2025 to $101.5 million at June 30, 2026, reflecting an $11.5 million cash outflow over six months amid ongoing losses that may pressure liquidity. (SEC Q2 10-Q, SEC Q1 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
908 Devices Financial Performance
Revenues and expenses
908 Devices Earnings Performance
Company profitability
Upcoming events
No upcoming events
908 Devices News
AllArticlesVideos
Funds containing 908 Devices
Fund name | Fund size | $MASS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.